First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The proposed study is a masked trial, with stratified block randomization by site, designed
to determine which treatment, methotrexate or mycophenolate mofetil, is more effective as
first-line steroid-sparing treatment for patients with non-infectious uveitis requiring
corticosteroid-sparing therapy.
One hundred non-infectious uveitis patients in need of corticosteroid-sparing therapy will be
randomized to receive either oral methotrexate or oral mycophenolate mofetil at Aravind Eye
Hospitals (Madurai and Coimbatore, South India). They will be followed monthly for 6 months
after enrollment or until treatment failure. The investigators hypothesize that the
proportion achieving corticosteroid-sparing success at 6 months for patients taking
mycophenolate mofetil will be improved in comparison with patients taking methotrexate.